Valneva SE (VALN)
VALN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1836564/000162828026018808/0001628280-26-018808-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | VALN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | France |
| IPO year | 2021 |
| SEC CIK | 0001836564 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | France |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $193.0M |
| Net income | -$127.3M |
| Operating income | -$90.7M |
| Net margin | -66.0% |
| Operating margin | -47.0% |
| Revenue growth | +3.0% |
| Cash | $121.2M |
| Total assets | $440.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.8× |
Reported in EUR; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-17 |
| Cash and burn | 109.7M EUR cash; operating cash flow -13.2M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 86,769,873 (2025-12-31); 81,260,762 a year earlier; 69,183,741 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-04 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Associés, Paris-La Défense, France | PCAOB Form AP 2026-04-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 174.7M EUR | -115.2M EUR | -52.9M EUR | 109.7M EUR | 179.2M EUR | 174.7M EUR | 20-F 2026-03-17 |
| FY 2024 2024-12-31 | 169.6M EUR | -12.2M EUR | -67.2M EUR | 168.3M EUR | 187.4M EUR | 169.6M EUR | 20-F 2026-03-17 |
| FY 2023 2023-12-31 | 153.7M EUR | -101.4M EUR | -202.7M EUR | 126.1M EUR | 176.8M EUR | 153.7M EUR | 20-F 2026-03-17 |
| FY 2022 2022-12-31 | 361.3M EUR | -143.3M EUR | -245.3M EUR | 286.5M EUR | 98.8M EUR | 361.3M EUR | 20-F 2025-03-24 |
| FY 2021 2021-12-31 | 348.1M EUR | -61.4M EUR | 76.9M EUR | 346.7M EUR | 57.8M EUR | 348.1M EUR | 20-F 2024-03-22 |
| FY 2020 2020-12-31 | 110.3M EUR | -55.1M EUR | 137.7M EUR | 204.4M EUR | 53.4M EUR | 110.3M EUR | 20-F 2023-03-30 |
| FY 2019 2019-12-31 | 126.2M EUR | -811K EUR | 5.5M EUR | 64.4M EUR | 26.3M EUR | 126.2M EUR | 20-F 2022-03-24 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-06-16 |
| Latest annual report | 20-F | 2026-03-17 |
| Latest quarterly / interim | 6-K | 2026-11-13 |
Source: SEC EDGAR submissions feed, 270 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.7% |
| 1 month | +1.8% |
| 3 months | +0.2% |
| Year to date | -35.8% |
| 1 year | -38.7% |
| From 52-week high | -52.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENTX | Entera Bio Ltd. | $3.02 | -2.89% | $525.9M |
| ETRA | Electra Therapeutics Inc. | $8.31 | -6.00% | $522.4M |
| DNA | Ginkgo Bioworks Holdings Inc. | $8.50 | -11.55% | $551.0M |
| IAM | Iambic Therapeutics Inc. | $11.85 | -9.54% | $561.7M |
| SANA | Sana Biotechnology Inc. | $1.88 | -6.93% | $563.3M |
| RGNX | REGENXBIO Inc. | $7.32 | -4.19% | $484.0M |
| SRZN | Surrozen Inc. | $32.32 | +2.25% | $616.1M |
| CGEM | Cullinan Therapeutics Inc. | $9.50 | -7.59% | $616.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier